Emergent BioSolutions Inc. EBS 深 沪
等待开盘 07-03 09:30:00 美东时间
8.16
-0.120
-1.45%
华盛通- 最 高8.53
- 今 开8.345
- 成交量 22.78万股
- 最 低 8.115
- 昨 收 8.28
- 总市值 4.21亿
- 52周最高 14.06
- 市盈率 静 8.80
- 换手率 0.44%
- 52周最低 5.615
- 委 比 5.66%
- 总股本 5159.63万
- 历史最高 137.61
- 量 比 0.42
- 振 幅 5.01%
- 历史最低 1.42
- 每 手 1
- 风险率 1.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Emergent BioSolutions 获得新ACAM2000生物防御合同
Emergent BioSolutions（股票代码EBS）披露最新业务及资本市场相关动态。 2026年6月26日，公司收到美国卫生与公众服务部ASPR授予的价...
06-30 10:34
Emergent BioSolutions获5270万美元天花疫苗合同
Emergent BioSolutions获得美国卫生与公众服务部价值5270万美元的合同修订订单，供应ACAM2000天花疫苗、配套耗材及替代批次稀释剂，预计...
06-29 21:25
Emergent BioSolutions Secures $52.7M U.S. Government Contract Modification For ACAM2000 Smallpox And Mpox Vaccine Supply
Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000® (Smallpox and Mpox (Vaccinia) V...
06-29 21:13
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government
Emergent BioSolutions has been awarded a $52.7 million contract modification by the U.S. Department of Health and Human Services to supply ACAM2000® vaccine for smallpox and mpox preparedness. The company emphasizes its role in biodefense and highlights recent approvals in Saudi Arabia and Singapore for expanded use of the vaccine. ACAM2000® is indicated for high-risk individuals and carries important safety warnings, including potential serious ...
06-29 13:13
Emergent BioSolutions Wins $64.5M U.S. HHS Contract Modification To Supply Botulism Antitoxin BAT Under Existing 10-Year Agreement
Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division
05-29 04:22
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions Inc. has been awarded a $64.5 million contract modification from the U.S. Department of Health and Human Services to supply BAT®, an antitoxin for treating botulism, under a 10-year agreement. The company highlights its commitment to U.S. biodefense and preparedness, leveraging its North American supply chain to deliver critical medical countermeasures. BAT® is indicated for treating symptomatic botulism in adults and pediat...
05-28 20:01
Emergent BioSolutions to present at Jefferies Global Healthcare Conference
Emergent BioSolutions to present at Jefferies Global Healthcare Conference Emergent BioSolutions will take part in investor conferences running May 27-29, May 28, June 2-4, and June 8-10. Conference appearances include the Goldman Sachs Leveraged Finance and Credit Conference, the Jefferies Global H
05-20 19:30
Emergent BioSolutions to Participate in Upcoming Investor Conferences
Emergent BioSolutions Inc. announced that its senior management team will participate in several investor conferences, including the Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, Jefferies Global Healthcare Conference, and Goldman Sachs 47th Annual Global Healthcare Conference. The company, which focuses on developing protective and life-saving solutions ...
05-20 11:30
Emergent BioSolutions Announces Saudi Approval For ACAM2000, Its Smallpox and Mpox Vaccine
Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine,
05-18 21:02
Saudi regulator SFDA approves Emergent ACAM2000 vaccine for smallpox, mpox prevention
Saudi regulator SFDA approves Emergent ACAM2000 vaccine for smallpox, mpox prevention Emergent BioSolutions won Saudi Food and Drug Authority registration for ACAM2000, a live vaccinia vaccine for prevention of smallpox and mpox in people deemed at high risk. The clearance marks the company’s first
05-18 20:59
